Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $38.18 in the prior trading day, Agios Pharmaceuticals Inc (NASDAQ: AGIO) closed at $37.71, down -1.23%. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 0.47 million shares were traded. AGIO stock price reached its highest trading level at $38.78 during the session, while it also had its lowest trading level at $37.38.
Ratios:
Our goal is to gain a better understanding of AGIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.04 and its Current Ratio is at 14.48. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 24, 2025, initiated with a Buy rating and assigned the stock a target price of $58.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 27 ’25 when Scadden David sold 200 shares for $40.00 per share. The transaction valued at 8,000 led to the insider holds 17,603 shares of the business.
DAVID T. SCADDEN bought 200 shares of AGIO for $8,000 on Aug 27 ’25. On Aug 08 ’25, another insider, Goff Brian, who serves as the Chief Executive Officer of the company, sold 11,085 shares for $36.67 each. As a result, the insider received 406,487 and left with 123,528 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 2191007488 and an Enterprise Value of 1300831232. As of this moment, Agios’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.60 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 31.825 whereas that against EBITDA is -2.851.
Stock Price History:
The Beta on a monthly basis for AGIO is 0.87, which has changed by -0.15694165 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, AGIO has reached a high of $62.58, while it has fallen to a 52-week low of $23.42. The 50-Day Moving Average of the stock is 1.67%, while the 200-Day Moving Average is calculated to be 4.81%.
Shares Statistics:
The stock has traded on average 748.51K shares per day over the past 3-months and 592750 shares per day over the last 10 days, according to various share statistics. A total of 58.04M shares are outstanding, with a floating share count of 54.39M. Insiders hold about 6.39% of the company’s shares, while institutions hold 108.49% stake in the company. Shares short for AGIO as of 1755216000 were 4815561 with a Short Ratio of 6.43, compared to 1752537600 on 4179173. Therefore, it implies a Short% of Shares Outstanding of 4815561 and a Short% of Float of 8.3500005.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.96, with high estimates of -$1.75 and low estimates of -$2.2.
Analysts are recommending an EPS of between -$6.99 and -$7.65 for the fiscal current year, implying an average EPS of -$7.38. EPS for the following year is -$7.06, with 7.0 analysts recommending between -$5.85 and -$9.34.
Revenue Estimates
8 analysts predict $10.49M in revenue for the current quarter. It ranges from a high estimate of $12.5M to a low estimate of $9M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $8.96MFor the next quarter, 8 analysts are estimating revenue of $14.14M. There is a high estimate of $15.9M for the next quarter, whereas the lowest estimate is $11.8M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $47.9M, while the lowest revenue estimate was $42.8M, resulting in an average revenue estimate of $45.85M. In the same quarter a year ago, actual revenue was $36.5MBased on 8 analysts’ estimates, the company’s revenue will be $115.63M in the next fiscal year. The high estimate is $161.76M and the low estimate is $87.72M.
